A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A six-month update.

Andrew Wei,Pau Montesinos,Vladimir Ivanov,Courtney D. DiNardo,Jan Novak,Kamel Laribi,Inho Kim,Don A. Stevens,Walter Fiedler,Maria Pagoni,Olga Samoilova,Jianxiang Wang,Achilles Anagnostopoulos,Julie Bergeron,Jing-Zhou Hou,Takahiro Yamauchi,Qi Jiang,Wellington Luiz Mendes,John Hayslip,Panayiotis Panayiotidis

A phase III study of venetoclax plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (VIALE-C): A six-month update.

2020

7511Background: VIALE-C was designed to compare the safety and efficacy of the BCL-2 inhibitor venetoclax (VEN) or placebo (PBO) plus low-dose cytarabine (LDAC) in previously untreated patient (pts...

Keywords:

Oncology
Venetoclax
Myeloid leukemia
Internal medicine
Pathology
older patients
low dose cytarabine
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations